PANews 11月15日消息，据Spot On Chain监测，除了Wintermute之外，GSR Markets已成为TARS AI的市场做市商。昨日，GSR ...

深潮 TechFlow 消息，11 月 15 日，据 Spot On Chain 监测，GSR Markets 或已成为 TARS AI（TAI）的市场做市商。昨日，GSR Markets 收到了 500 万枚 TAI（约合 78.9 ...

Tarsus Pharmaceuticals在财务业绩的上下线方面持续表现出色，促使该公司修正其估计和目标价。公司的XDEMVY自推出以来仅一年多就实现了约2.5亿美元的年化销售额。这一成功导致该公司决定将产品的销售预测上调两位数百分比，超过了此前对2024年第一季度的估计。

Tarsus Pharmaceuticals Inc (TARS) reports its most successful quarter with $48 million in net sales, expanded coverage, and a ...

Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number of shares changing hands ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Shares of Tarsus Pharmaceuticals, Inc. (TARS) have gained 22.4% over the past four weeks to close the last trading session at $44.83, but there could still be a solid upside left in the stock if short ...

Tarsus Pharmaceuticals, Inc. (TARS) 宣布2024年第三季度业绩强劲，其眼科治疗产品XDEMVY（用于治疗蠕形螨睑缘炎（DB）和睑板腺功能障碍（MGD））的净产品销售额创下4800万美元的纪录。公司已扩大销售团队，并获得了广泛的商业和医疗保险覆盖。 Tarsus还计划在2024年底前获得两种额外治疗方法的FDA批准，并预计XDEMVY将在2027年下半年获得欧洲批 ...

The Indian Golf Union (IGU) is set to host its first-ever level 3 Tournament Administrators and Referees Seminar (TARS) in April next year, marking a major milestone for the sport in the country. “We ...